Fig. 1
TGF-β2 and LC3B are highly expressed in glioma and co-localized with each other indicating poor prognosis in glioma patients. a Immunochemistry (IHC) showed more LC3B and TGF-β2 positive cells in GBM than normal brain (scale bars, 100μm). b IRS model quantatively analyzed LC3B and TGF-β2 expression levels in IHC and the correlationship between the two factors. c Relationship between TGF-β2 and autophagy related factors were calculated with Pearson index by data from REMBRANDT. d Immunofluorescent analysis of LC3B (green) and (red) co-localization in glioma and normal brain tissue (scale bars, 200μm, enlarged 50μm). e qRT-PCR analyses were compared between normal brain and glioma patients. f Chi-square analysis of age, gender or LC3B/TGF-β2 expression levels with glioma grades. g Long-rank monovariate analysis test in 63 glioma patients. h Survival curve about patients with TGF-β (+)/TGF-β (-) and TGF-β (+)/LC3B (+) were distinguished from TGF-β (+)/LC3B (-)